PRINCIPLES OF MODERN IMMUNOTHERAPY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, immunotherapy is the most promising method of treating malignant tumors. This review considers the main principles of its action: universality, inertiA., dualism, and the complexity of directed action. The original classification of immunotherapy methods according to the mechanism of their action is presented, which allows better understanding the features of individual methods of treatment. Methods for evaluating the effectiveness of immunotherapeutic agents and immuno-mediated adverse events are discussed in detail. Understanding and using the principles of immunotherapy discussed in the article will allow to optimize the use of immunooncological drugs and to maximally protect the patient from possible adverse events associated with their use.

Full Text

Restricted Access

About the authors

A. V Novik

N.N. Petrov National Medical Research Center of Oncology; SPbSPU of RMH

Email: anoyik@list.ru
PhD, Senior Researcher at the Division of Oncoimmunology, Physician at the Department of Chemotherapy and Innovative Technologies; Associate Professor at the Department of Oncology, Children’s Oncology and Radiation Therapy St. Petersburg, Russia

References

  1. Новик А.В., Балдуева И.А., Нехаева Т.Л. Принципы применения современной иммунотерапии в онкологии Материалы конференции «Клеточные технологии практическому здравоохранению». Екатеринбург, 2016. С. 98-100.
  2. Middleton M., Hauschild A., Thomson D., et al. Results of a multicenter random-ized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann Oncol. 2007; 10:1691-97.
  3. Wolchok J.D., Chiarion-Sileni V, Gonzalez R., et al. Overall Survival with Com-bined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017;14:1345-56.
  4. Schadendorf D., Hodi F.S., Robert C., et al. Pooled Analysis of Long-Term Surviv-al Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Mela-noma. J. Clin. Oncol. 2015:17:1889-94.
  5. Reck M., Rodriguez-Abreu D., Robinson A.G., et el. Pembrolizumab versus Chem-otherapy for PD-L1-Positive Non-Small-Cell Lung Cancer N. Engl. J. Med. 2016:19:1823-33.
  6. Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015;17:1627-39.
  7. Brahmer J., Reckamp K.L., Baas P., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015;2:123-35.
  8. Murakami S., Özgüroglu M., Villegas A., et al. PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with stage III, locally advanced, unresectble NSCLC. Ann. Oncol. 2017(suppl_10):x122-x3.
  9. Weber J., Mandala M., Del Vecchio M., et al. Adjuvant Nivolumab versus Ipili-mumab in Resected Stage III or IV Melanoma. N. Engl. J. Med. 2017: 19:1824-35.
  10. Chang L., Chang M., Chang H.M. Chang F. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Appl. Immunohistochem. Mol. Morphol. 2018;2:e15-e21.
  11. Schreiber R.D., Old L.J. Smyth M.J. Cancer immunoediting: integrating immuni-ty's roles in cancer suppression and promotion. Science. 2011;6024:1565-70.
  12. Alexandrov L.B., Nik-Zainal S., Wedge D.C., et al. Signatures of mutational pro-cesses in human cancer. Nature. 2013;7463:415-21.
  13. Shurin M.R., Umansky V., Malyguine A., eds. The tumor immunoenvironment. New York, 2013.
  14. Ярилин A.A. Иммунология: учебник для вузов по специальностям 060101.65 «Лечебное дело» и 060104.65 «Медико-профилактическое дело». M., 2010. 749 с.
  15. DeVita V.T. Jr, Lawrence T.S., Rosenberg S.A. DevitA., Hellman, and Rosenberg's cancer: principles & practice of oncology. 10th edition. PhiladelphiA., 2015.
  16. Oflazoglu E., Audoly L.P. Evolution of anti-CD20 monoclonal antibody therapeu-tics in oncology. MAbs. 2010;1:14-9.
  17. Xin H., Zhang C., Herrmann A., et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009;6:2506-13.
  18. Латипова Д.Х., Проценко C.A., Новик A.B., и др. Место эфферентной тера-пии в лечении солидных опухолей. Вопр. онкол. 2015;2:174-79.
  19. Larkin J.M.G., Lewis K.D., Ribas A., et al. Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM). J. Clin. Oncol. 2017;15(suppl):9556.
  20. Yoon S.H., Kim K.W., Goo J.M., et al. Observer variability in RECIST-based tu-mour burden measurements: a meta-analysis. Eur. J. Cancer 2016;53:5-15.
  21. Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 2009;23:7412-20.
  22. Hamid O., Puzanov I., Dummer R., et al. Final analysis of a randomised trial com-paring pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory ad-vanced melanoma. Eur. J. Cancer. 2017;86:37-45.
  23. George S., Motzer R.J., Hammers H.J., et al. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016;9:1179-86.
  24. Balar A.V., Galsky M.D., Rosenberg J.E., et al. Atezolizumab as first-line treat-ment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a singlearm, multicentre, phase 2 trial. Lancet. 2017; 10064:67-76.
  25. Antonia S.J., Villegas A., Daniel D., et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017;20:1919-29.
  26. Weber J.S., Gibney G., Sullivan R.J., et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;7:943-55.
  27. Bersanelli M., Leonetti A., Buti S., Michiara M. «Finding NEMO» in NRAS-mutant melanoma: a step towards a sequential strategy? Lancet Oncol. 2017;6:e298.
  28. Lotem M., Merims S., Frank S., et al. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. J. Immunol. Res. 2016. Article ID 8121985.
  29. Bedikian A.Y., Johnson M.M., Warneke C.L., et al. Systemic therapy for unresec-table metastatic melanoma: impact of biochemotherapy on long-term survival. J. Immunotoxicol. 2008;2:201-7.
  30. Новик А.В., Новик В.И., Моисеенко В.М. Значение плоидности ДНК в определении прогноза диссеминированной меланомы кожи и оценке эффективности лечения интерлейкином-2. Вопросы онкологии. 2007;2:158-63.
  31. Wang Q., Gao J.Wu.X. Pseudoprogression and hyperprogression after checkpoint blockade. Int. Immunopharmacol. 2018;58:125-35.
  32. Bellmunt J., de Wit R., Vaughn D.J., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N. Engl. J. Med. 2017;11:1015-26.
  33. Yang A., Baxi S., Korenstein D. ClinicalTrials.gov for Facilitating Rapid Under-standing of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. J. Oncol. Pract. 2018;2:72-6.
  34. Koenig H.C., Sutherland A., Izurieta H.S., McGonagle D. Application of the im-munological disease continuum to study autoimmune and other inflammatory events after vaccination. Vaccine. 2011;5:913-99.
  35. Проценко С.А., Антимоник Н.Ю., Берштейн Л.М., и др. Практические рекомендации по коррекции иммуноопосредованных нежелательных явлений. Злокачественные опухоли: Практические рекомендации RUSSCO. 2017;3(s2):592-620.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies